RayKnowChina Research Map
Shortlist

Not yet recruitingCoronary heart diseaseN/A

Registered title, quoted from ClinicalTrials.gov

Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction

An open trial on coronary heart disease, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFuwai Hospital中国医学科学院阜外心血管病医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07678021, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Women who are pregnant or breastfeeding;

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07678021, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The subject is aged ≥18 years;
  • The subject has been diagnosed with chronic or acute coronary syndrome and has a left ventricular ejection fraction <35%;
  • After comprehensive evaluation by the cardiac team, it is considered that the subject may benefit from PCI treatment;
  • The subject has signed an informed consent form approved by the ethics committee, has good compliance after discharge, and is willing to undergo clinical follow-up.
  • At least two vascular occlusive lesions (with the diameter of the occluded vessel >2.5mm) or unprotected left main coronary artery disease, and meeting one or more complex procedural criteria, or three-vessel disease, and meeting two or more complex procedural criteria;

Exclusion Criteria:

  • Received mechanical circulatory assistance devices (including IABP, ECMO, Impella, etc.) before randomization;
  • Acute myocardial infarction within 7 days or undergoing thrombolytic therapy;
  • Combined with aortic dissection, pulmonary embolism, or severe pulmonary hypertension;
  • Patients with cardiogenic shock or hemodynamic instability;
  • Cardiopulmonary resuscitation was performed before randomization;
  • Mechanical complications (including ventricular perforation, interventricular septal perforation, mitral valve chordae rupture, etc.) confirmed before randomization and subsequent to acute myocardial infarction;
  • The mechanical circulatory assist device cannot be implanted or there are contraindications (including but not limited to left ventricular mural thrombus, artificial aortic valve or cardiac contractile device, moderate or severe aortic stenosis, moderate or severe aortic regurgitation, presence of stents in peripheral vascular access, tortuosity, dissection, and other severe vascular lesions that hinder the implantation of the investigational device, aortic aneurysm or severe malformation abnormalities, blood cell fragility or hemolytic blood system diseases, hypertrophic or hypertrophic obstructive cardiomyopathy, etc.);
  • Severe abnormalities in platelets, with a count below 50×10\^9/L or above 600×10\^9/L;
  • Active visceral hemorrhage or hemorrhagic stroke occurs within 1 month;
  • Unable to use antiplatelet or anticoagulant drugs;
  • Has a history of drug allergy and cannot tolerate conventional cardiovascular drug therapy and intraoperative medications;
  • Severe renal insufficiency, requiring or expected to require long-term dialysis treatment;
  • Severe active infection, puncture site infection, sepsis, or septicemia;
  • Life expectancy is less than or equal to 1 year;
  • Women who are pregnant or breastfeeding;
  • Severe right heart failure or severe tricuspid regurgitation;
  • Participation in other clinical trials has not yet reached the primary endpoint;
  • Other situations that are unforeseen or deemed unsuitable by the researcher's comprehensive judgment.

Quoted from ClinicalTrials.gov, NCT07678021, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07678021, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07678021